Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Fox

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
CSF Proteomics and Machine Learning Reveal Distinct Stages Across the Alzheimer's Disease ContinuumSaima Rathore, Eric B Dammer, Anantharaman Shantaraman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 30, 2017
Mutational spectra of aflatoxin B<sub>1</sub> in vivo establish biomarkers of exposure for human hepatocellular carcinomaSupawadee Chawanthayatham, Charles C Valentine, Bogdan I Fedeles, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2018
A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference ProceedingsAndrew R Romeo, Robert P Lisak, Ethan Meltzer, et al.
Cancer|April 17, 2020
Long-term causes of death among pediatric patients with cancerSamantha R Horn, Kelsey C Stoltzfus, Heath B Mackley, et al.
Neurology|July 31, 2020
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE studyAmit Bar-Or, Jonathan C Calkwood, Cathy Chognot, et al.
Nature Protocols|October 10, 2014
Detecting ultralow-frequency mutations by Duplex SequencingScott R Kennedy, Michael W Schmitt, Edward J Fox, et al.
Frontiers in Neurology|November 8, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosisEnrique Alvarez, Lawrence Steinman, Edward J Fox, et al.
Nature Communications|May 12, 2023
Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer's diseaseZhi Huang, Gennifer E Merrihew, Eric B Larson, et al.
Neuroscience Insights|October 9, 2023
Unveiling Resilience to Alzheimer's Disease: Insights From Brain Regional Proteomic MarkersZhi Huang, Gennifer E Merrihew, Eric B Larson, et al.
Frontiers in Immunology|June 15, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosisDerrick Robertson, Enrique Alvarez, Lawrence Steinman, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
CSF Proteomics and Machine Learning Reveal Distinct Stages Across the Alzheimer's Disease ContinuumSaima Rathore, Eric B Dammer, Anantharaman Shantaraman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 30, 2017
Mutational spectra of aflatoxin B<sub>1</sub> in vivo establish biomarkers of exposure for human hepatocellular carcinomaSupawadee Chawanthayatham, Charles C Valentine, Bogdan I Fedeles, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2018
A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference ProceedingsAndrew R Romeo, Robert P Lisak, Ethan Meltzer, et al.
Cancer|April 17, 2020
Long-term causes of death among pediatric patients with cancerSamantha R Horn, Kelsey C Stoltzfus, Heath B Mackley, et al.
Neurology|July 31, 2020
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE studyAmit Bar-Or, Jonathan C Calkwood, Cathy Chognot, et al.
Nature Protocols|October 10, 2014
Detecting ultralow-frequency mutations by Duplex SequencingScott R Kennedy, Michael W Schmitt, Edward J Fox, et al.
Frontiers in Neurology|November 8, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosisEnrique Alvarez, Lawrence Steinman, Edward J Fox, et al.
Nature Communications|May 12, 2023
Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer's diseaseZhi Huang, Gennifer E Merrihew, Eric B Larson, et al.
Neuroscience Insights|October 9, 2023
Unveiling Resilience to Alzheimer's Disease: Insights From Brain Regional Proteomic MarkersZhi Huang, Gennifer E Merrihew, Eric B Larson, et al.
Frontiers in Immunology|June 15, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosisDerrick Robertson, Enrique Alvarez, Lawrence Steinman, et al.
Pageof 13